New Research Collaboration Will Boost Search for Low Molecular Weight Drugs
By LabMedica International staff writers Posted on 02 Nov 2015 |
A collaborative agreement between American and Danish biopharmaceutical companies is expected to advance the discovery of new low molecular weight drugs.
Nuevolution A/S (Copenhagen, Denmark) has announced that it has entered into a collaborative agreement with Janssen Biotech, Inc. (Horsham, PA, USA). Janssen is a subsidiary of the international medical devices, pharmaceutical, and consumer packaged goods manufacturer Johnson & Johnson (New Brunswick, NJ, USA).
The collaboration is intended to generate new low molecular weight drugs by exploiting Nuevolution’s proprietary Chemetics drug discovery platform. Chemetics is a unique, patent protected drug discovery platform for both identification and optimization of hit to drug candidates. It is a hybrid of proven wet chemistry and molecular biology that enables DNA encoded synthesis of billions of chemically diverse drug-like small molecule compounds, and the efficient screening and optimization of these, facilitating effective identification of drug candidates at an unprecedented speed and scale.
Within the framework of the collaboration, Nuevolution will apply its Chemetics platform to discover and advance drug candidates against drug targets of interest to Janssen. Under the terms of the agreement, Nuevolution will receive an upfront payment, research funding, and would be eligible to milestone payments upon achievement of specified research, development, and commercial milestones. In addition, Nuevolution would be entitled to receive certain royalty payments on net-sale of products that may be commercialized as a result of the collaboration.
“We are excited about entering into the extensive collaboration with Janssen,” said Alex Gouliaev, CEO of Nuevolution A/S. “We are looking forward to an excellent working relationship with their dedicated research and development teams.”
Related Links:
Nuevolution A/S
Janssen Biotech, Inc.
Johnson & Johnson
Nuevolution A/S (Copenhagen, Denmark) has announced that it has entered into a collaborative agreement with Janssen Biotech, Inc. (Horsham, PA, USA). Janssen is a subsidiary of the international medical devices, pharmaceutical, and consumer packaged goods manufacturer Johnson & Johnson (New Brunswick, NJ, USA).
The collaboration is intended to generate new low molecular weight drugs by exploiting Nuevolution’s proprietary Chemetics drug discovery platform. Chemetics is a unique, patent protected drug discovery platform for both identification and optimization of hit to drug candidates. It is a hybrid of proven wet chemistry and molecular biology that enables DNA encoded synthesis of billions of chemically diverse drug-like small molecule compounds, and the efficient screening and optimization of these, facilitating effective identification of drug candidates at an unprecedented speed and scale.
Within the framework of the collaboration, Nuevolution will apply its Chemetics platform to discover and advance drug candidates against drug targets of interest to Janssen. Under the terms of the agreement, Nuevolution will receive an upfront payment, research funding, and would be eligible to milestone payments upon achievement of specified research, development, and commercial milestones. In addition, Nuevolution would be entitled to receive certain royalty payments on net-sale of products that may be commercialized as a result of the collaboration.
“We are excited about entering into the extensive collaboration with Janssen,” said Alex Gouliaev, CEO of Nuevolution A/S. “We are looking forward to an excellent working relationship with their dedicated research and development teams.”
Related Links:
Nuevolution A/S
Janssen Biotech, Inc.
Johnson & Johnson
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples